COMP <GO>
CADL vs SLDB // EV/EBITDA & P/E VALUATION
Candel Therapeutics Inc. (NASDAQ) VS. Solid Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: CADL 2
— SLDB 2
■ METRIC PARITY
LAST: $8.65 (-0.23%) • MKT CAP: $661.9M
valuation
—
LAST: $6.39 (-1.39%) • MKT CAP: $685.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CADL VS. SLDB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CADL | SLDB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.88% | -22.98% | +17.10 | CADL | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | CADL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.7 | 42.4 | -4.66 | SLDB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $661.9M | $685.2M | -$23.3M | SLDB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CADL REV | SLDB REV | CADL GROSS % | SLDB GROSS % | CADL FCF | SLDB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$38.9M | -$157.4M |
| FY 2024 | $0 | $0 | — | — | -$27.0M | -$100.7M |
| FY 2023 | $0 | — | — | — | -$34.2M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CADL // BETA —
SLDB // BETA —